Identifies therapeutic alternatives during drug shortages with clinical equivalence assessment. Use when managing drug shortages, finding alternative therapies, or implementing shortage protocols.
Identifies therapeutic alternatives during drug shortages with clinical equivalence assessment, conservation strategies, and communication protocols.
Drug shortages are a persistent and growing threat to patient safety in the United States, with over 300 active shortages reported annually by the ASHP Drug Shortage Resource Center and the FDA Drug Shortage Database. Shortages affect critical medications including injectable opioids, chemotherapy agents, IV fluids, antibiotics, and electrolyte replacements. ASHP surveys indicate that 99% of hospital pharmacists have managed at least one drug shortage, and 47% report that shortages have contributed to medication errors.
The causes are multifactorial: manufacturing quality failures (FDA 483 citations), raw material supply chain disruptions, just-in-time inventory practices, limited manufacturing redundancy, and economic disinvestment in low-margin generic injectables. The Drug Shortage Staffing Assessment (ASHP 2019) found that hospital pharmacists spend an average of 8.6 hours per week managing drug shortages. ASHP Guidelines on Managing Drug Product Shortages provide the standard framework: identify the shortage, assess clinical impact, develop therapeutic alternatives, implement conservation strategies, communicate to stakeholders, and monitor outcomes. Failure to manage shortages systematically leads to treatment delays, suboptimal substitution, medication errors, and patient harm.
Verify shortage status through official sources:
Classify shortage severity:
| Severity Level | Definition | Response Timeframe |
|---|---|---|
| Critical | No therapeutic alternative available; life-threatening impact | Immediate (within hours) |
| High | Alternatives exist but require significant clinical adjustment | Within 24-48 hours |
| Moderate | Alternatives are clinically equivalent and available | Within 1 week |
| Low | Shortage affects convenience but not clinical outcomes | Standard process |
Assess institutional impact:
For each clinical indication served by the shortage drug, identify alternatives:
Alternative assessment framework:
| Evaluation Criteria | Alternative A | Alternative B | Alternative C |
|---|---|---|---|
| Drug name and dose | |||
| Route and formulation | |||
| Clinical equivalence evidence | |||
| Pharmacokinetic differences | |||
| Safety profile comparison | |||
| Current formulary status | |||
| Supply chain stability | |||
| Cost comparison | |||
| Monitoring requirement changes | |||
| Required dose conversion |
Common shortage scenarios and alternatives:
| Shortage Drug | Typical Alternatives | Key Considerations |
|---|---|---|
| Normal saline IV bags | Lactated Ringer's, PlasmaLyte | Avoid LR with citrate-sensitive products |
| IV push opioids (morphine, hydromorphone) | Oral opioids (if GI functional), PCA, fentanyl IV | Equianalgesic conversion required |
| Norepinephrine | Phenylephrine, vasopressin, epinephrine | Different receptor profiles; clinical impact |
| Sodium bicarbonate injection | Tromethamine (THAM) for specific indications | Not equivalent for all indications |
| Ondansetron IV | Granisetron IV, oral ondansetron, promethazine | Avoid promethazine IV push |
| Dextrose 50% | Dextrose 25% (double volume), glucagon IM | Different volume and administration |
Tier 1 — Immediate conservation (no clinical impact):
Tier 2 — Moderate conservation (minimal clinical adjustment):
Tier 3 — Critical conservation (significant clinical adjustment):
Stakeholder communication plan:
| Audience | Communication Method | Content | Timing |
|---|---|---|---|
| Pharmacists | Pharmacy department memo + staff meeting | Shortage details, alternatives, dispensing changes | Day 1 |
| Prescribers/medical staff | EHR banner, email, medical director notification | Shortage notice, approved alternatives, order changes | Day 1-2 |
| Nursing | Nursing communication, ADC alerts | New product preparation/administration, look-alike warnings | Day 1-2 |
| P&T Committee | Emergency therapeutic interchange notification | Alternative protocols for committee ratification | Per urgency |
| Administration | Impact summary for pharmacy leadership | Financial impact, supply timeline, risk assessment | Day 2-3 |
| Patients (if applicable) | Prescriber-led conversation, pharmacy counseling | Why medication is changing, expected equivalence | At transition |
Documentation requirements: